Correction to: Cell Death and Disease
https://doi.org/10.1038/s41419-020-03111-7 published online 24 October 2020
The original version of this Article was updated shortly after publication following a mistake at proof stage, which resulted in the wrong version of Figure 1 being uploaded. The figure has now been replaced with the correct version in both the PDF and HTML versions of the Article.
..
Author information
Authors and Affiliations
Corresponding authors
Additional information
Edited by S. Tait
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Feng, H., Liu, K., Shen, X. et al. Correction: Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5+ colorectal cancer. Cell Death Dis 11, 1006 (2020). https://doi.org/10.1038/s41419-020-03208-z
Published:
DOI: https://doi.org/10.1038/s41419-020-03208-z
